About: Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library
Creator	Bagheri, Vahid Motamedifar, Mohamad Nejatollahi, Foroogh Sahebkar, Amirhossein Amir, Abbas Esmaeili, Seyed Momtazi,
topic	covid:d84a2944db9e6904887a201afc129a6e14b334b8#this
Source	Elsevier; Medline; PMC
abstract	Abstract The HSV-1 envelope glycoprotein B (gB) plays a critical role in virus entry into host cells. Neutralizing antibodies can therefore potentially prevent virus entry into target cells and cell-to-cell spread of infection. Our present study focused on the selection of neutralizing single-chain Fv (scFv) antibodies of a phage-displayed nonimmune human scFv antibody library against gB of HSV-1. To enrich specific scFvs, two phage antibodies were isolated against amino acid residues 31–43 derived from the N-terminal part of gB using panning technique. Two scFvs, scFv-gB1 and scFv-gB2, with frequencies of 45% and 20% were obtained from scFv clones after performing PCR and MvaI fingerprinting. In phage ELISA analysis, both gB1 and gB2 scFvs demonstrated high reactivity with the gB peptide. In the neutralization assay, scFv-gB1 and scFv-gB2 represented neutralizing effects of 55% and 59%, respectively. Upon further enhancement of the neutralizing effects of these antibodies, they can be considered as new potential alternatives in the treatment and prophylaxis of HSV-1 infections.
has issue date	2017-01-15(xsd:dateTime)
bibo:doi	10.1016/j.lfs.2016.11.018
bibo:pmid	27888111
has license	els-covid
sha1sum (hex)	d84a2944db9e6904887a201afc129a6e14b334b8
schema:url	https://doi.org/10.1016/j.lfs.2016.11.018
resource representing a document's title	Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library
has PubMed Central identifier	PMC7094719
has PubMed identifier	27888111
schema:publication	Life Sciences
resource representing a document's body	covid:d84a2944db9e6904887a201afc129a6e14b334b8#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/d84a2944db9e6904887a201afc129a6e14b334b8
is schema:about of	named entity 'HUMAN' named entity 'DISPLAYED' named entity 'DISPLAYED' named entity 'PERFORMING' named entity 'NEUTRALIZING ANTIBODIES' named entity 'ELISA' named entity 'HSV-1' named entity 'FREQUENCIES' named entity 'VIRUS ENTRY' named entity 'ANTIBODIES' named entity 'PHAGE' named entity 'STUDY' named entity 'NEW' named entity 'FINGERPRINTING' named entity 'SCFV ANTIBODY' named entity 'FOCUSED' named entity 'REACTIVITY' named entity 'TARGET CELLS' named entity 'HUMAN' named entity 'ENVELOPE GLYCOPROTEIN B' named entity 'TREATMENT' named entity 'PART OF' named entity 'PEPTIDE' named entity 'ANALYSIS' named entity 'ENRICH' named entity 'DEMONSTRATED' named entity 'CONSIDERED' named entity 'ISOLATED' named entity 'ENTRY INTO HOST' named entity 'PANNING' named entity 'ANTIBODY LIBRARY' named entity 'GLYCOPROTEINS' named entity 'INFECTION' named entity 'ROLE' named entity 'INFECTIONS' named entity 'HIGH' named entity 'SPECIFIC' named entity 'OUR' named entity 'CLONES' named entity 'CELL' named entity 'PLAYS' named entity 'PRESENT' named entity 'SINGLE-CHAIN FV' named entity 'USING' named entity 'SCFV ANTIBODY' named entity 'RECOMBINANT ANTIBODIES' named entity 'PHAGE' named entity 'THESE' named entity 'PROPHYLAXIS OF' named entity 'DERIVED' named entity 'PREVENT' named entity 'SPREAD' named entity 'ASSAY' named entity 'ANTIBODY LIBRARY' named entity 'N-TERMINAL ' named entity 'EFFECTS' named entity 'SCFV' named entity 'PCR' named entity 'AMINO ACID' named entity 'TECHNIQUE' named entity '20%' named entity 'OBTAINED' named entity 'ENHANCEMENT' named entity 'HOST CELLS' named entity 'CRITICAL' named entity 'POTENTIAL' named entity 'HERPES SIMPLEX VIRUS TYPE 1' named entity 'SELECTION' covid:arg/d84a2944db9e6904887a201afc129a6e14b334b8 named entity 'assay' named entity 'infection' named entity 'scFv' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software